From the Departments of Oncology and Biochemistry & Molecular Biology, University of Calgary, Calgary, Alberta T2N 4N1, Canada
Received for publication, October 7, 2002, and in revised form, February 4, 2003
![]() |
ABSTRACT |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
The plasma membrane is not homogenous but
contains specific subcompartments characterized by their unique lipid
and protein composition. Based on their enrichment in various signaling
molecules, these membrane microdomains are recognized to be sites of
localized signal transduction for a number of extracellular stimuli. We have previously shown that fibroblast growth factor-2 (FGF2) induced a
specific signaling response within a lipid raft membrane microdomain in
human neuroblastoma cells characterized by the tyrosine phosphorylation of a p80 phosphoprotein. Herein, we show that this protein is the
signaling adaptor FRS2 and that it is localized exclusively to lipid
rafts in vitro and in vivo. We have examined
how the tyrosine phosphorylation and serine-threonine phosphorylation of FRS2 within lipid rafts affect the response of cells to FGF2 signaling. Our data suggest that activation of protein kinase C,
Src family kinases, and MEK1/2 are involved in regulating
serine-threonine phosphorylation of FRS2, which can indirectly affect
FRS2 phosphotyrosine levels. We also show that Grb2 is recruited to
lipid rafts during signaling events and that activation of MEK1/2 by
different mechanisms within lipid rafts may lead to different cellular
responses. This work suggests that compartmentalized signaling within
lipid rafts may provide a level of specificity for growth factor signaling.
Fibroblast growth factors
(FGFs)1 constitute a large
family of peptide hormones that influence a wide variety of biological processes such as angiogenesis, embryogenesis, differentiation, and
proliferation depending on the cell type (1, 2). In the nervous system,
FGFs have been shown to stimulate both the differentiation and survival
of post-mitotic cells as well as being proliferative factors for
non-differentiated cells (3). FGFs induce their biological effects by
binding to and activating a family of trans-membrane receptor
tyrosine kinases (FGFR1-4) (2, 4). The activation of the FGFRs occurs
by dimerization of the trans-membrane receptors upon the binding of the
FGF ligand followed by autophosphorylation of a number of tyrosine
residues, some of which can act as recruitment sites for various
downstream effectors (2, 4-6).
One relatively unique aspect of FGF signaling is the recruitment of
signaling molecules to FGFRs through the adaptor protein FGF receptor
substrate 2 (FRS2, a.k.a. Suc1-associated neurotrophic factor target or
SNT) (7, 8). FRS2 associates directly with FGFRs and shows increased
tyrosine phosphorylation upon FGFR signaling and functions to recruit
SH2 domain-containing proteins such as Grb2 that link the FGFR to a
variety of downstream pathways (7, 9, 10). FRS2 also exhibits a high
level of serine-threonine as well as tyrosine phosphorylation (7, 10).
The function of the serine-threonine phosphorylation on FRS2 is
presently unclear, although it may provide another level of specificity
to the FGFR signaling by regulating pathways distinct from those
associated with the tyrosine phosphorylation of FRS2. The importance of
FRS2 in FGF signaling is reflected in the embryonic lethal phenotype observed during mouse development after disruption of the
FRS2 gene. In addition, FRS2 null cell lines derived from
these embryos show an impairment of FGF-induced migration,
proliferation, and MAPK activation (11).
FGFR signaling also leads to activation of members of the Src protein
tyrosine kinase family (12). Studies on Xenopus
laevis have demonstrated that Laloo, a novel member of the
Src family of tyrosine kinases, is required for mesoderm induction in
response to FGF (13). The cooperation of FRS2 and Laloo in this pathway is suggested by the observed association of FRS2 with Laloo (14, 15).
Although many receptor tyrosine kinases activate similar downstream
pathways such as the MAPK pathway, they induce specific phenotypic
responses from the cell. Specificity can be achieved temporally by the
developmentally regulated expression of certain components of the
pathways. For instance, the expression of different FGFR types is
regulated during oligodendrocyte maturation, providing a molecular
basis for the developmentally varying response of cells to a common
ligand (16). Specificity can also originate from the type of receptor
expressed, because all of the FGFRs do not appear to have the same
efficiency at activating various downstream pathways (17-19). In
addition, the location of the receptor or downstream events within the
cell may add another level of specificity in the signaling response.
Microdomains within the plasma membrane such as lipid rafts function to
sequester signaling molecules and act as sites of signal transduction
that can regulate cell physiology (20-22). Lipid rafts are
characterized by their enrichment in glycosphingolipids and cholesterol
as well as by their unique protein composition (20, 22). On the inner
leaflet of the plasma membrane, proteins such as G-proteins and members
of the Src-family of protein tyrosine kinases are found associated with
these membrane microdomains (23-25). There are at least two different
microcompartments that can be distinguished by their shape and protein
composition (22). Caveolae are one such compartment characterized by
the presence of caveolin-1, a 22-kDa protein known as the structural
component of these small flask-shaped caves (26-29). Originally,
caveolae were thought to function in receptor-mediated
potocytosis (30). However, their functions are rapidly expanding
to include events such as an alternative route of receptor endocytosis,
trans-cytosis, regulation of calcium homeostasis, a site of clustering
of glycosylphosphatidylinositol-linked proteins, and more
recently, a localized site for signal transduction (20, 30-34).
Previously, we had observed an FGF2-induced signaling event that was
localized to membrane microdomains that we termed caveolae-like domains
(35). Herein, we have identified the FGF2-responsive protein FRS2 as a
lipid raft-associated protein, both in vitro and in the
developing mouse brain. We have also examined FGF2 signaling through
FRS2 within lipid rafts and show that serine-threonine phosphorylation
of FRS2 is dependent on a pathway involving protein kinase C (PKC), Src
family kinases, and MEK1/2 and that FGF2 signaling through MEK1/2 may
have different phenotypic consequences in the cell depending upon the
pathway used for activation of MEK1/2.
Antibodies--
Anti-FRS2 polyclonal antibody was from Santa
Cruz Biotechnology Inc. (Santa Cruz, CA); anti-Grb2 and anti-PKC
monoclonal antibodies were obtained from Transduction Laboratories
(Lexington, KY); 4G10 anti-phosphotyrosine was from Upstate
Biotechnology Inc. (Lake Placid, NY); anti-active MAPK polyclonal was
purchased from Promega (Madison, WI); and anti-MAPK was from
Zymed Laboratories Inc. (San Francisco, CA).
Cell Culture--
LAN-1 cells were cultured in
Dulbecco's modified Eagle's medium supplemented with 10% cosmic
calf serum (Hyclone) and 1% penicillin/streptomycin at 37 °C in 5%
CO2. Prior to growth factor treatment, cells were serum-starved in Dulbecco's modified Eagle's medium with 0.5% cosmic
calf serum for 18 h. Cells were stimulated with 20 ng/ml FGF2, 50 ng/ml 12-O-tetradecanoylphorbol-13-acetate (TPA), or 100 nM thymeleatoxin for the times indicated in experiments.
Inhibitor studies were done with the addition of 10 µM
PP2 or PP3, 1 µM bisindolylmaleimide (Bis) I or V, or 10 µM U0126 to the cells for 30 min prior to cell stimulation.
Immunoprecipitation and Western Blotting--
Cells were rinsed
once with phosphate-buffered saline, pH 7.4, and lysed in 1% Nonidet
P-40 lysis buffer (50 mM HEPES, pH 7.5, 150 mM
NaCl, 1.5 mM MgCl2, 1 mM EGTA, 10%
glycerol, 1% Nonidet P-40 (protein grade; Calbiochem), 1 mM PMSF (Roche Molecular Biochemicals), 1 mM
sodium orthovanadate, and 10 µg/ml each of aprotinin and leupeptin
(Sigma)). Insoluble material was removed by centrifugation at
12000 × g for 15 min at 4 °C. Cell-free lysates
were incubated with 1 µg/ml FRS2 polyclonal antibody for 1 h at
4 °C. Protein A-Sepharose was added, and the mixtures were incubated
for an additional 30 min at 4 °C. The immunocomplexes were washed
several times with 1% Nonidet P-40 lysis buffer, and the samples were boiled in 2× SDS Laemmli's sample buffer prior to separation on 10%
SDS-polyacrylamide gels. Following electrophoresis, the proteins were
transferred to nitrocellulose membranes (Schleicher & Schuell). Membranes were dried and blocked in Tris-buffered saline (5 mM Tris, 135 mM NaCl, and 5 mM KCl)
containing 0.1% Nonidet P-40, 0.1% Tween 20, and 5% bovine serum
albumin for 20 min. Membranes were then incubated for 1 h with a
1:1000 dilution of the appropriate antibodies in their respective
blocking buffers. The membranes were washed extensively in
Tris-buffered saline containing 0.1% Nonidet P-40 and 0.1% Tween 20 or 0.5% Nonidet P-40 and 0.1% Tween 20 when Isolation of Detergent-insoluble Low Density
Fractions--
Cells were grown to confluence on 150-mm-diameter
dishes and stimulated as described above. Cells were rinsed in ice-cold phosphate-buffered saline and lysed in 1% Triton X-100 buffer. The
cells were fractionated on sucrose gradients, and low density soluble
and pelleted fractions were isolated as described in detail previously
(23).
Preparation of Mouse Brain Homogenate--
CD1 mouse embryos
were recovered at stages E11, E16, and P1. Whole brain tissue
was isolated and homogenized in 1% Triton X-100 buffer before
fractionation on sucrose gradient and isolation of low density
fractions as described above.
Identification of FRS2 as a Lipid Raft-associated
Protein--
Previous work from our laboratory has shown that FGF2 was
unique from other growth factors (epidermal growth factor and
platelet-derived growth factor) and neurotrophins in that it was able
to induce a compartmentalized signaling response in a human
neuroblastoma cell line, LAN-1 (35). In our previous work, we referred
to these membrane microdomains as caveolae-like domains, because the
LAN-1 cells expressed both caveolin-1 and -2. However, since we have
only characterized this membrane fraction based on its detergent
insolubility and low buoyant density fractionation, it is more
appropriate to refer to these domains as lipid rafts, consistent with
recent nomenclature (36).
We observed that FGF2 was able to induce an increase in tyrosine
phosphorylation of several proteins within the lipid raft fraction
including an unknown protein migrating between 75-80 kDa that
bound to glutathione S-transferase fusion proteins
containing p13suc1 or Src-SH2 domains (35). Association with p13suc1 or SH2 domains is a feature of the 80-kDa FGFR-associated adaptor protein,
FRS2, and related family members (7, 8, 10). Therefore, in an attempt
to characterize and identify the p75-80 protein, we used antibodies
directed to FRS2 to probe fractionated LAN-1 cell lysates that had been
treated with 20 ng/ml FGF2 for 5 min. Western blotting showed that FRS2
is localized exclusively to lipid raft fractions and correlates with
the FGF2-induced phosphotyrosine seen at 80 kDa in the lipid raft
fraction (Fig. 1A). A 90-kDa band was also observed in the Triton X-100-soluble and pelleted fractions when Western blotting for FRS2 (Fig. 1A). This
band was never observed to be tyrosine-phosphorylated in response to FGF2, so it is probably a nonspecific band or possibly a FGF
non-responsive FRS2-related protein. Immunoprecipitation of FRS2 from
whole cell lysates confirmed that the 80-kDa FRS2 was
tyrosine-phosphorylated in response to FGF2 (Fig. 1B).
Therefore, we have identified FRS2 as a FGF2-responsive protein that is
localized specifically to the lipid raft fraction of LAN-1 cells.
To establish that this localization was not unique to established cell
lines, we also examined the expression and localization of FRS2 at
various time points in the developing mouse brain. Whole mouse brain
lysates were fractionated on sucrose gradients and probed by Western
blotting for FRS2 expression. We found that FRS2 was expressed at each
of the stages of development examined and that in all stages FRS2 was
specifically localized to the lipid raft fractions (Fig.
1C).
Serine-Threonine Phosphorylation of FRS2 Is Regulated by Protein
Kinase C, Src Family Kinase, and MEK1/2 Activity--
The
FRS2 response to FGF2 stimulation is characterized by an increased
tyrosine phosphorylation as well as a change in electrophoretic mobility on SDS-PAGE gels that has been attributed to the action of
serine-threonine kinases toward FRS2 (10). Therefore, we have used the
mobility shift as an indicator of FRS2 serine-threonine levels. Because
FGFRs have been shown to activate phospholipase C
Using a 5-min stimulation of 20 ng/ml FGF2, we could visualize the
shift in electrophoretic mobility of FRS2, indicative of its
serine-threonine phosphorylation (Fig.
2A). The effects of FGF2 on
FRS2 could be blocked by PP2, an inhibitor of the Src family kinases,
or the PKC inhibitor Bis I, suggesting that PKC and Src family kinase
activity are required for FGF2-induced serine-threonine phosphorylation
of FRS2 (Fig. 2A). FGF2-induced serine-threonine phosphorylation of FRS2 was also completely blocked by the MEK1/2 inhibitor U0126, suggesting that activation of the MAPK cascade is also
required for serine-threonine phosphorylation of FRS2. The
electrophoretic shift in mobility in FRS2 using FGF2 treatment could be
replicated using 50 ng/ml TPA, a diacyl glycerol analog that activates
conventional and novel PKC isoforms (Fig. 2A), as well as
when cells were stimulated with thymeleatoxin, which specifically
activates conventional isoforms of PKC (data not shown) (39). The
electrophoretic mobility shift of FRS2 induced by TPA could also be
abrogated in the presence of PP2, Bis I, or U0126 inhibitors. These
data confirmed that direct activation of PKC could lead to
serine-threonine phosphorylation of FRS2 and that it was also dependent
on downstream activation of Src family kinases and MEK1/2 as observed
for FGF2 stimulation. FRS2 was only detected in lipid raft fractions
and not in the Triton X-100-soluble fraction of the cells (Fig.
2A).
An analysis of Western blots showing phosphotyrosine levels in lipid
rafts revealed that FGF2 treatment induced tyrosine phosphorylation of
FRS2, which was not blocked by pretreatment of the cells with PP2, Bis
I, or U0126 (inhibitors that blocked serine-threonine phosphorylation
of FRS2). Rather, under these conditions, tyrosine phosphorylation of FRS2 appeared to be enhanced (Fig. 2A).
Unlike FGF2, treatment of the cells with TPA did not result in the
increased tyrosine phosphorylation of FRS2 (Fig. 2A). These
results suggest that serine-threonine phosphorylation of FRS2 is not
required for tyrosine phosphorylation of FRS2 to occur and that
blocking the serine-threonine phosphorylation of FRS2 can lead to
enhanced tyrosine phosphorylation.
Tyrosine-phosphorylated FRS2 has been shown to directly recruit Grb2
and activate the MAPK pathway in response to FGF2 (40, 41). We also
confirmed that Grb2 associates in a complex with FRS2 in LAN-1 cells as
determined by immunoprecipitation of FRS2 (data not shown). Because
FRS2 was associated exclusively with lipid rafts, we examined the level
of Grb2 recruitment to lipid rafts after cell stimulation. Grb2 was
present in the Triton X-100-soluble cell fraction under all of the
conditions examined (Fig. 2A). Under control conditions,
Grb2 was either not present in lipid rafts or at extremely low levels.
FGF2 stimulation induced the recruitment of Grb2 to lipid rafts, and
this was not blocked by PP2, Bis I, or U0126, which blocked
serine-threonine phosphorylation of FRS2. As was observed for tyrosine
phosphorylation of FRS2, it appeared that Grb2 recruitment to lipid
rafts was actually enhanced under conditions that inhibit
serine-threonine phosphorylation of FRS2 (Fig. 2A). TPA
treatment did not induce Grb2 recruitment to lipid rafts, although some
Grb2 was present after TPA treatment in the presence of U0126 (Fig.
2A). These data suggest that serine-threonine phosphorylation of FRS2 is neither sufficient nor necessary for the
recruitment of Grb2 to lipid rafts; however, enhancing tyrosine phosphorylation of FRS2 recruits more Grb2 to lipid rafts. Equal loading of the lipid raft fractions was confirmed by Western blotting for caveolin protein levels (Fig. 2A).
Protein kinase C Isoforms Show Differential Association with Lipid
Rafts--
To address which PKC isoform might be involved in FRS2
signaling, we looked at the expression of PKC isoforms in fractionated LAN-1 cells to determine whether there was any localization to lipid
raft microdomains. Several PKC isoforms were expressed in LAN-1 cells;
however, PKC Activation of MAPK by FGF2 Is Not Dependent on Serine-Threonine
Phosphorylation of FRS2--
We have already shown that Grb2 is
recruited to tyrosine-phosphorylated FRS2 in lipid rafts in the absence
of FRS2 serine-threonine phosphorylation. We next examined whether the
serine-threonine phosphorylation levels of FRS2 affected downstream
MAPK activation.
After the treatment of LAN-1 cells with 20 ng/ml FGF2 for 5 min, FRS2
was immunoprecipitated and examined by SDS-PAGE for a change in
electrophoretic mobility under various inhibitory conditions. Using the
Src family kinase inhibitor PP2 or the PKC family inhibitor Bis
I, we observed an inhibition of the change in mobility of FRS2 induced
by FGF2 treatment. The inhibitory effects of PP2 and Bis I were not
observed when the control compound, PP3 or Bis V, was used (Fig.
3A). As observed previously,
neither PP2 nor Bis I inhibited the tyrosine phosphorylation of FRS2; however, there was an increase in the tyrosine phosphorylated FRS2 seen
at 75 kDa that corresponds to the accumulation of FRS2 in the
non-serine-threonine-phosphorylated form (Fig. 3A).
Whole cell lysates from cells treated with the same conditions were
used to determine the phosphorylation levels of MAPK. It was found that
FGF2 activated p42ERK and that neither PP2 nor Bis I
blocked MAPK activation by FGF2 (Fig. 3B). These data
suggest that MAPK activation correlates with FRS2 tyrosine
phosphorylation, whereas global serine-threonine phosphorylation of
FRS2 is not required for the propagation of signals that lead to MAPK activation.
FGF2 Induces Cell-rounding Morphology That Is Dependent on MEK
Activity but Not PKC--
LAN-1 cells that were treated with 20 ng/ml
FGF2 for 18 h showed a change from a flattened dendritic
morphology to a rounded refractile morphology (Fig.
4A). This change in morphology
was not seen when the cells were treated with 50 ng/ml TPA or 100 nM thymeleatoxin for the same time period (Fig.
4A). When the cells were pretreated with the MEK inhibitor
U0126, the FGF2-induced cell rounding was completely blocked and the
cells remained in a flattened adherent morphology (Fig. 4B).
In contrast, the pretreatment of the cells with the PKC inhibitor Bis I
failed to inhibit the FGF2-induced cell rounding (Fig. 4B).
Together, these results suggest that FGF2 acts to induce cell rounding
through a MEK-dependent pathway and that this pathway does
not require the activation of PKC.
In summary, we have shown that FRS2 is a lipid raft-associated
protein, both in the cell culture model used here and also in vivo. We have also shown that FGF2 signaling
through FRS2 involves multiple pathways that appear to regulate
distinct phenotypic responses in the cell.
FRS2 was initially described as an adaptor protein involved in FGF
signaling that was modified at the N terminus with the addition of a
myristoylation moiety (7). The acyl modification functions to target
FRS2 to the membrane, and several reports (7, 40) have shown that FRS2
is indeed localized to the membrane portion of fractionated cells and
that membrane association is required for efficient signaling to occur
through FRS2. Here, we have shown that FRS2 is not only targeted to the
plasma membrane but that it is localized specifically to lipid rafts
within the membrane, both in cultured LAN-1 cells and also in lipid
rafts isolated from various stages of developing mouse brain.
Many signaling molecules have been reported to be present within lipid
rafts, and membrane microdomains are thought to act as sights for
regulated formation of signal transduction complexes that influence
downstream signaling from a variety of membrane receptors (22). The
localization of FRS2 to lipid rafts is probably important in regulating
its interaction with other molecules such as bringing FRS2 into close
proximity with FGFR to enable the association of the two proteins that
has been demonstrated to occur between the juxtamembrane region of FGFR
and the phosphotyrosine binding domain of FRS2 (42). FRS2 is
known to be expressed in the developing nervous system (43). Our
observation that FRS2 is also localized to lipid rafts in developing
mouse brain provides evidence that this localization may be
functionally important for efficient signaling through FRS2
in vivo during neural development.
We have been unable to determine whether any of the FGFRs are
localized to lipid rafts (35), possibly because of the fact that the
receptors are extracted from the lipid raft fraction under the
conditions used as has been noted for the epidermal growth factor
receptor (44).
FRS2 contains several tyrosine residues that have been shown to be
phosphorylated in response to growth factor signaling (7, 8). The
tyrosine phosphorylation of FRS2 is important in signal propagation and
has been shown to be required for association with Grb2 and downstream
activation of the MAPK pathway (40, 42) as well as in the recruitment
of several other signaling molecules such as Cbl (45) and
phosphatidylinositol 3-kinase (46). However, it has also been shown
that the majority of phosphorylation on FRS2 is on serine and threonine
rather than tyrosine (7, 10). Previous reports of the molecular weight
of FRS2 have varied somewhat, possibly because of the change in
electrophoretic mobility that is associated with serine-threonine
kinase activity toward FRS2 (10). In this report, we have examined the
tyrosine and serine-threonine levels of FRS2 under various conditions
to determine the effect they have on FRS2 signaling within lipid rafts.
It has previously been shown that phospholipase C During the preparation of this paper, it has been demonstrated that the
activation of MAPK results in serine phosphorylation of FRS2, which
acts to negatively regulate the tyrosine
phosphorylation-dependent signaling through FRS2 (50). We
also observed that the inhibition of serine-threonine phosphorylation
of FRS2 leads to increased tyrosine phosphorylation levels of FRS2 as
well as a correlating increase in the level of Grb2 recruited to lipid
rafts that suggests a negative regulation of FRS2 phosphotyrosine by
serine-threonine phosphorylation. Although Lax et al.
(50) did not find PKC activity to be required for the
serine-threonine phosphorylation of FRS2 to occur, we have shown that
PKC is involved in serine-threonine phosphorylation of FRS2 in LAN-1
cells, possibly through MEK1/2-dependent activation of MAPK.
Both FGF and TPA have been shown to activate the Ras/MAPK signaling
cascade in a PKC-dependent manner (51), and it is possible
that PKC-dependent activation of Ras in response to FGF2 is
only utilized by certain cell types or under certain conditions.
Our data also suggest a requirement for the activation of MEK1/2 in
both FGF2- and TPA-stimulated serine-threonine phosphorylation of FRS2.
However, only FGF2 stimulation recruits Grb2 to lipid rafts and induces
LAN-1 cell rounding in a MEK1/2-dependent manner. This
would suggest that despite both FGF2 and TPA activating a MEK1/2-dependent pathway, only the FGF2-activated MEK1/2
leads to LAN-1 cell rounding. The data presented here suggest that FGF2 may activate MEK1/2 through the recruitment of Grb2 to FRS2 and also by
activation of Ras by PKC. The activation of MEK1/2 through these
different mechanisms may lead to different downstream responses in the
cell as has been noted in other cell types where activation of
different isoforms of PKC lead to differential localization of MAPK
within the cell, leading to different cellular responses (37). A model
showing FRS2 signaling pathways is shown in Fig. 5.
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
-phosphotyrosine
antibody was used. This was followed by incubation for 20 min with
appropriate horseradish peroxidase-conjugated secondary antibodies
(Amersham Biosciences), each diluted 1:10000 in blocking buffer. The
membranes were washed as described above and developed using an ECL substrate.
RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
View larger version (67K):
[in a new window]
Fig. 1.
Localization of FRS2 to lipid rafts.
Cells were lysed in 1% Triton X-100 buffer and fractionated on sucrose
gradients to allow isolation of lipid raft fractions along with Triton
X-100-soluble and insoluble fractions. A, LAN-1 cells were
treated with 20 ng/ml FGF2 for 5 min prior to lysis and fractionation.
Blotting for phosphotyrosine showed an 80-kDa protein that was
phosphorylated in response to FGF2 that occurs specifically in the
lipid raft fraction. Antibodies to FRS2 showed that FRS2 is also
localized specifically to lipid rafts and corresponds to the
phosphorylated protein at 80 kDa. B, LAN-1 cells were
treated with 20 ng/ml FGF2 for 5 min, and the cell-free lysate was used
for immunoprecipitation with antibodies to FRS2. Immunoprecipitated
FRS2 was tyrosine-phosphorylated in response to FGF2. C,
embryonic mouse brain was isolated and lysed prior to fractionation on
sucrose gradients. Blotting for FRS2 showed FRS2 localization to lipid
raft fractions but not Triton X-100-soluble fractions of the mouse
brain.
(38), which can
lead to the activation of PKC, we examined the possibility that PKC was
involved in serine-threonine phosphorylation of FRS2.
View larger version (58K):
[in a new window]
Fig. 2.
Characterization of FRS2 serine-threonine and
tyrosine phosphorylation-dependent signaling in lipid
rafts. LAN-1 cells were stimulated with either 20 ng/ml FGF2 or 50 ng/ml TPA and then lysed in 1% Triton X-100 buffer and fractionated on
sucrose gradients to allow isolation of lipid raft fractions along with
Triton X-100-soluble fractions. A, Western blotting for FRS2
shows that FGF2 induced serine-threonine phosphorylation of FRS2 that
was blocked by pretreatment of the cells with PP2, Bis I, or U0126. TPA
also induced the serine-threonine phosphorylation of FRS2 and was
blocked by pretreatment of the cells with PP2, Bis I, or U0126.
Examination of phosphotyrosine levels showed that FGF2 treatment lead
to tyrosine phosphorylation of FRS2, which was enhanced by PP2, Bis I,
or U0126 treatment. TPA treatment did not stimulate tyrosine
phosphorylation of FRS2. Analysis of Grb2 levels showed that Grb2 was
present in the soluble fractions but not in the raft fractions and was
recruited to lipid rafts upon FGF2 stimulation. The recruitment of Grb2
to lipid rafts was enhanced by treatment with PP2 or U0126. Caveolin
levels confirm equal loading of lipid raft fractions. B,
LAN-1 cells fractionated on sucrose gradients were blotted for
expression of PKC isoforms. PKC , PKC
, and PKC
were all
expressed, but only PKC
showed strong localization to lipid raft
fractions.
was the only isoform detected that showed strong lipid
raft association, although the localization of PKC
did not appear to
be affected by FGF2 treatment (Fig. 2B). Of the other
conventional PKC isoforms, PKC
was excluded from lipid rafts (Fig.
2B) and PKC
was not detected in Western blots (data not
shown), suggesting that PKC
may be the isoform involved in signaling
through FRS2 in LAN-1 cells.
View larger version (75K):
[in a new window]
Fig. 3.
FGF2-induced MAPK activation does not require
serine-threonine phosphorylation of FRS2. LAN-1 cells were treated
with 20 ng/ml FGF2 after a 30-min preincubation with either 10 µM PP2 or PP3 or 1 µM Bis I or Bis V and
then lysed in 1% Nonidet P-40 lysis buffer and subject to
immunoprecipitation with antibodies to FRS2. A, examination
of FRS2 showed that FGF2-induced serine-threonine phosphorylation was
inhibited by treatment with PP2 or Bis I but not control compounds PP3
or Bis V. FGF2-induced tyrosine phosphorylation of FRS2 was not
affected by either inhibitor. B, whole cell lysates treated
the same as above were examined for MAPK activation. FGF2 addition lead
to MAPK activation, and this was not inhibited by PP2 or Bis I
treatment.
View larger version (82K):
[in a new window]
Fig. 4.
FGF2-induced cell rounding requires MAPK but
not PKC. LAN-1 cells were treated with 20 ng/ml FGF2 or 50 ng/ml
TPA or 100 nM thymeleatoxin for 18 h after
pretreatment with either 10 µM U0126 or 1 µM Bis I. A, FGF2 treatment induced the
rounding of the cells, whereas TPA and thymeleatoxin only had a slight
effect on cell rounding. B, FGF2-induced cell rounding was
blocked by inhibition of MEK using U0126 but not inhibition of PKC
using Bis I.
DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
associates
directly with the FGFR through its SH2 domain and is involved in FGF
signaling (38). Because phospholipase C is an upstream activator of PKC
signaling, we examined the possibility that PKC was involved in the
serine-threonine phosphorylation of FRS2. It has been reported that
FRS2 associates with the atypical isoform PKC
, although it was not
found to be a substrate of PKC
in vitro (47).
Our data suggest that a conventional PKC isoform is involved in the
phosphorylation of FRS2, although in agreement with previous studies,
FRS2 may not be a direct substrate of PKC because we observed an
inhibition of TPA-induced serine-threonine phosphorylation of FRS2 by
both PP2 and U0126 treatment, suggesting a requirement for Src family
kinase and MEK1/2 activity downstream of PKC. PKC can associate with
Src family kinases through adaptor proteins, and tyrosine
phosphorylation of PKC has been implicated in the modulation of
downstream signaling (48, 49). Of the three conventional PKC isoforms,
we have shown that the PKC
isoform is present in lipid rafts,
whereas the PKC
isoform is excluded from lipid rafts isolated from
LAN-1 cells. The PKC
isoform was not detected (data not shown).
Therefore, it is possible that PKC
is the isoform involved in either
direct or indirect phosphorylation of FRS2 in LAN-1 cells.
View larger version (29K):
[in a new window]
Fig. 5.
A putative model for FGF-induced
phosphorylation of FRS2 and downstream signaling. Tyrosine
phosphorylation of FRS2 (Y), possibly through the action of
the tyrosine kinase receptor itself, leads to activation of MAPK
through multiple pathways. Serine-threonine phosphorylation of FRS2
(S and T) involving PKC and Src family kinases
leads to the activation of pathways distinct from those downstream of
FRS2 tyrosine phosphorylation but still involve MEK. Whether MAPK is
the direct mediator of the PKC-dependent pathway remains to
be determined.
In addition to FGF, a diverse array of signaling molecules has been shown to utilize lipid rafts for various aspects of their signaling mechanisms (36). We have previously shown that the glycosylphosphatidylinositol-anchored ephrins are also able to induce a compartmentalized signaling response within the lipid rafts of cells including neural cells. As is the case for FGF, ephrin signaling induces the phosphorylation of a p75-80 phosphoprotein (35); however, this protein is not FRS2.2 Therefore, there is specificity of signaling within lipid rafts through the recruitment of different signaling molecules to distinct signaling pathways
In summary, we have shown that the FGF-responsive adaptor protein FRS2
is localized exclusively to lipid rafts within the cell membrane and
that this localization is probably an important factor in the
regulation of signaling via FRS2 through the regulation of interacting
signaling molecules that either regulate the phosphorylation of FRS2 or
are responsive to FRS2 phosphorylation levels. We have also shown that
MEK1/2 is involved in multiple signaling pathways within lipid rafts
and that the activation of MEK1/2 through different mechanisms may lead
to different cellular responses.
![]() |
ACKNOWLEDGEMENTS |
---|
We thank the members of the laboratory for their constructive comments and discussions during the course of this work. We also thank Dr. Alice Davy for valuable input during the initial stages of this work.
![]() |
FOOTNOTES |
---|
* This work was supported by a grant from the Canadian Institutes of Health Research.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
Supported by an Alberta Cancer Board fellowship.
§ Senior Scholar of the Alberta Heritage Foundation for Medical Research and holds a Canada Research Chair in Cancer Biology. To whom correspondence should be addressed: Depts. of Oncology and Biochemistry & Molecular Biology, 3330 Hospital Dr., N. W., University of Calgary, Calgary, Alberta T2N 4N1, Canada. Tel.: 403-220-4054; Fax: 403-283-2787; E-mail: srobbins@ucalgary.ca.
Published, JBC Papers in Press, February 5, 2003, DOI 10.1074/jbc.M210245200
2 A. Davy, M. S. Ridyard, and S. M. Robbins, unpublished data.
![]() |
ABBREVIATIONS |
---|
The abbreviations used are: FGF, fibroblast growth factor; FGFR, FGF receptor; SH, Src homology; PKC, protein kinase C; TPA, 12-O-tetradecanoylphorbol-13-acetate; Bis, bisindolylmaleimide; FRS2, fibroblast growth factor receptor substrate 2; PKC, protein kinase C; ERK, extracellular signal-regulated kinase; MAPK, mitogen-activated protein kinase; MEK, mitogen-activated protein kinase/extracellular signal-regulated kinase kinase.
![]() |
REFERENCES |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
1. | Basilico, C., and Moscatelli, D. (1992) Adv. Cancer Res. 59, 115-165[Medline] [Order article via Infotrieve] |
2. | Galzie, Z., Kinsella, A. R., and Smith, J. A. (1997) Biochem. Cell Biol. 75, 669-685[CrossRef][Medline] [Order article via Infotrieve] |
3. | Gritti, A., Parati, E. A., Cova, L., Frolischthal, P., Galli, R., Wanke, E., Favarelli, L., Morassutti, D. J., Roisen, F., Nickel, D. D., and Vescovi, A. L. (1996) J. Neurosci. 16, 1091-1100[Abstract] |
4. | Jaye, M., Schlessinger, J., and Dionne, C. A. (1992) Biochim. Biophys. Acta 1135, 185-199[Medline] [Order article via Infotrieve] |
5. | Schlessinger, J., and Ullrich, A. (1992) Neuron 9, 383-391[Medline] [Order article via Infotrieve] |
6. | Ullrich, A., and Schlessinger, J. (1990) Cell 61, 203-212[Medline] [Order article via Infotrieve] |
7. | Kouhara, H., Hadari, Y. R., Spivak-Kroizman, T., Schilling, J., Bar-Sagi, D., Lax, I., and Schlessinger, J. (1997) Cell 89, 693-702[Medline] [Order article via Infotrieve] |
8. | Rabin, S. J., Cleghon, V., and Kaplan, D. R. (1993) Mol. Cell. Biol. 13, 2203-2213[Abstract] |
9. |
Goh, K. C.,
Lim, Y. P.,
Ong, S. H.,
Siak, C. B.,
Cao, X.,
Tan, Y. H.,
and Guy, G. R.
(1996)
J. Biol. Chem.
271,
5832-5838 |
10. | Wang, J.-K., Xu, H., Li, H.-C., and Goldfarb, M. (1996) Oncogene 13, 721-729[Medline] [Order article via Infotrieve] |
11. |
Hadari, Y. R.,
Gotoh, N.,
Kouhara, H.,
Lax, I.,
and Schlessinger, J.
(2001)
Proc. Natl. Acad. Sci. U. S. A.
98,
8578-8583 |
12. | Kuo, W.-L., Chung, K.-C., and Rosner, M. R. (1997) Mol. Cell. Biol. 17, 4633-4643[Abstract] |
13. | Weinstein, D. C., Marden, J., Carnevali, F., and Hemmati-Brivanlou, A. (1998) Nature 394, 904-908[CrossRef][Medline] [Order article via Infotrieve] |
14. |
Kusakabe, M.,
Masuyama, N.,
Hanafusa, H.,
and Nishida, E.
(2001)
EMBO Rep.
2,
727-735 |
15. |
Hama, J.,
Suri, C.,
Haremaki, T.,
and Weinstein, D. C.
(2002)
J. Biol. Chem.
277,
19806-19810 |
16. | Bansal, R., Kumar, M., Murray, K., Morrison, R. S., and Pfeiffer, S. E. (1996) Mol. Cell. Neurosci. 7, 263-275[CrossRef][Medline] [Order article via Infotrieve] |
17. |
Lin, H. Y.,
Xu, J.,
Ischenko, I.,
Ornitz, D. M.,
Halegoua, S.,
and Hayman, M. J.
(1998)
Mol. Cell. Biol.
18,
3762-3770 |
18. | Ornitz, D. M., Xu, J., Colvin, J. S., McEwen, D. G., MacArthur, C. A., Coulier, F., Gao, G., and Goldfarb, M. (1996) J. Biol. Chem. 271, 1592-15297 |
19. | Wang, J.-K., Gao, G., and Goldfarb, M. (1994) Mol. Cell. Biol. 14, 181-188[Abstract] |
20. | Anderson, R. G. W. (1998) Annu. Rev. Biochem. 67, 199-225[CrossRef][Medline] [Order article via Infotrieve] |
21. | Schlegel, A., Volonte, D., Engelman, J. A., Galbiati, F., Mehta, P., Zhang, X.-L., Scherer, P. E., and Lisanti, M. P. (1998) Cell. Signalling 10, 457-463[CrossRef][Medline] [Order article via Infotrieve] |
22. | Simons, K., and Ikonen, E. (1997) Nature 387, 569-572[CrossRef][Medline] [Order article via Infotrieve] |
23. | Robbins, S. M., Quintrell, N. A., and Bishop, J. M. (1995) Mol. Cell. Biol. 15, 3507-3515[Abstract] |
24. | Sargiacomo, M., Sudol, M., Tang, Z., and Lisanti, M. P. (1993) J. Cell Biol. 122, 789-809[Abstract] |
25. | Shenoy-Scaria, A. M., Dietzen, D. J., Kwong, J., Link, D. C., and Lublin, D. M. (1994) J. Cell Biol. 126, 353-363[Abstract] |
26. | Fra, A. M., Williamson, E., Simons, K., and Parton, R. G. (1995) Proc. Natl. Acad. Sci. U. S. A. 92, 8655-8659[Abstract] |
27. |
Lipardi, C.,
Mora, R.,
Colomer, V.,
Paladino, S.,
Nitsch, L.,
Rodriguez-Boulan, E.,
and Zurzulo, C.
(1998)
J. Cell Biol.
140,
617-626 |
28. | Monier, S., Parton, R., Vogel, F., Behlke, J., Henske, A., and Kurzchalia, T. (1995) Mol. Biol. Cell 6, 911-927[Abstract] |
29. | Rothberg, K. G., Heuser, J. E., Donzell, W. C., Ying, Y.-S., Glenney, J. R., and Anderson, R. G. W. (1992) Cell 68, 673-682[Medline] [Order article via Infotrieve] |
30. | Anderson, R. G. W., Kamen, B. A., Rothberg, K. G., and Lacey, S. W. (1992) Science 255, 410-411[Medline] [Order article via Infotrieve] |
31. | Anderson, R. G. W. (1993) Curr. Opin. Cell Biol. 5, 647-652[Medline] [Order article via Infotrieve] |
32. | Fujimoto, T. (1993) J. Cell Biol. 120, 1147-1157[Abstract] |
33. | Fujimoto, T., Nakade, S., Miyawaki, A., Mikoshiba, K., and Ogawa, K. (1992) J. Cell Biol. 119, 1507-1513[Abstract] |
34. | Schnitzer, J. E. (1997) in Vascular Endothelium: Physiology, Pathology and Therapeutic Opportunities (Born, G. V. R. , and Schwartz, C. J., eds) , pp. 77-95, Schattauer, Stuttgart, Germany |
35. | Davy, A., Feuerstein, C., and Robbins, S. M. (2000) J. Neurochem. 74, 676-683[CrossRef][Medline] [Order article via Infotrieve] |
36. |
Zajchowski, L. D.,
and Robbins, S. M.
(2002)
Eur. J. Biochem.
269,
737-752 |
37. | Besson, A., Davy, A., Robbins, S. M., and Yong, V. W. (2001) Oncogene 20, 7398-7407[CrossRef][Medline] [Order article via Infotrieve] |
38. | Mohammadi, M., Honegger, A. M., Rotin, D., Fischer, R., Bellot, F., Li, W., Dionne, C. A., Jaye, M., Rubinstein, M., and Schlessinger, J. (1991) Mol. Cell. Biol. 11, 5068-5078[Medline] [Order article via Infotrieve] |
39. | Llosas, M. D., Batlle, E., Coll, O., Skoudy, A., Fabre, M., and Garcia de Herreros, A. (1996) Biochem. J. 315, 1049-1054[Medline] [Order article via Infotrieve] |
40. | Ong, S. H., Goh, K. C., Lim, Y. P., Low, B. C., Klint, P., Claesson-Welsh, L., Cao, X., Tan, Y. H., and Guy, G. R. (1996) Biochem. Biophys. Res. Commun. 225, 1021-1026[CrossRef][Medline] [Order article via Infotrieve] |
41. |
Xu, H.,
and Goldfarb, M.
(2001)
J. Biol. Chem.
276,
13049-13056 |
42. |
Xu, H.,
Lee, K. W.,
and Goldfarb, M.
(1998)
J. Biol. Chem.
273,
17987-17990 |
43. | McDougall, K., Kubu, C., Verdi, J. M., and Meakin, S. O. (2001) Mech. Dev. 103, 145-148[CrossRef][Medline] [Order article via Infotrieve] |
44. |
Mineo, C.,
Gill, G. N.,
and Anderson, R. G.
(1999)
J. Biol. Chem.
274,
30636-30643 |
45. |
Wong, A.,
Lamothe, B.,
Li, A.,
Schlessinger, J.,
and Lax, I.
(2002)
Proc. Natl. Acad. Sci. U. S. A.
99,
6684-6689 |
46. |
Ong, S. H.,
Hadari, Y. R.,
Gotoh, N.,
Guy, G. R.,
Schlessinger, J.,
and Lax, I.
(2001)
Proc. Natl. Acad. Sci. U. S. A.
98,
6074-6079 |
47. |
Lim, Y. P.,
Low, B. C.,
Lim, J.,
Wong, E. S.,
and Guy, G. R.
(1999)
J. Biol. Chem.
274,
19025-19034 |
48. | Schechtman, D., and Mochly-Rosen, D. (2001) Oncogene 20, 6339-6347[CrossRef][Medline] [Order article via Infotrieve] |
49. |
Kronfeld, I.,
Kazimirsky, G.,
Lorenzo, P. S.,
Garfield, S. H.,
Blumberg, P. M.,
and Brodie, C.
(2000)
J. Biol. Chem.
275,
35491-35498 |
50. | Lax, I., Wong, A., Lamothe, B., Lee, A., Frost, A., Hawes, J., and Schlessinger, J. (2002) Mol. Cell 10, 709-719[Medline] [Order article via Infotrieve] |
51. | Liu, J. F., Crepin, M., Liu, J. M., Barritault, D., and Ledoux, D. (2002) Biochem. Biophys. Res. Commun. 293, 1174-1182[CrossRef][Medline] [Order article via Infotrieve] |